Reuters logo
1 年前
BRIEF-Celldex Therapeutics says initiates phase 1/2 study of Glembatumumab Vedotin in squamous cell lung cancer
2016年4月27日 / 下午12点32分 / 1 年前

BRIEF-Celldex Therapeutics says initiates phase 1/2 study of Glembatumumab Vedotin in squamous cell lung cancer

April 27 (Reuters) - Celldex Therapeutics Inc

* Says initiates phase 1/2 study of Glembatumumab Vedotin in squamous cell lung cancer

* Says first stage of phase 2 portion will enroll approximately 20 patients Source text for Eikon: Further company coverage: )

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below